No Picture
Boston Cambridge Biotech Trending News

Blue Cross Blue Shield of Massachusetts Releases Statement on U.S. District Court Ruling Invalidating Requirement for Free Preventive Services

BOSTON, March 30, 2023 /PRNewswire/ — In response to U.S. District Judge Reed O’Connor’s ruling to invalidate a major provision of the Affordable Care Act (ACA) requiring free preventive care services, Blue Cross Blue Shield […]

No Picture
Boston Cambridge Biotech Trending News

Humanitarian training offered in Turkish, Ukrainian

March 29, 2023 – Those responding to ongoing needs following the devastating earthquakes in Turkey in February now have access to online humanitarian training modules in Turkish, thanks to an effort from the Building a […]

No Picture
Boston Cambridge Biotech Trending News

Women Making Modest Progress Breaking into High-Paying Executive Jobs, Yet Still Face Barriers to the CEO’s Office

Women’s Power Gap research quantifies the glass ceiling in Massachusetts’ 75 largest public companies*, showing a 60% drop-off for women in final ascent to CEO role. BOSTON, March 29, 2023 /PRNewswire/ — Newly released data […]

Boston Cambridge Biotech Trending News

Transforming Lives for Generations: A dive into the core of a patient-driven innovation approach and culture

MassBio will join with Boehringer Ingelheim on May 9 for the Boehringer Ingelheim Transforming Science Day 2023 in the MassBioHub, a Pharma Day®-style opportunity for the local life sciences industry to get the latest insights […]

No Picture
Boston Cambridge Biotech Trending News

Lucy Therapeutics Appoints Neuroscience Drug Discovery and Development Expert Christopher J. Winrow, Ph.D., as Chief Scientific Officer

WALTHAM, Mass.–(BUSINESS WIRE)–Lucy Therapeutics, Inc., a private biotech company developing proprietary mitochondrial-based small molecule therapies and biomarkers for neurological diseases, today announced the appointment of Christopher J. Winrow, Ph.D., a neuroscience and translational medicine expert, […]

No Picture
Boston Cambridge Biotech Trending News

Blueprint Medicines Announces Lift of Partial Clinical Hold on Phase 1/2 VELA Trial of BLU-222

CAMBRIDGE, Mass., March 28, 2023 /PRNewswire/ — Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that the U.S. Food and Drug Administration (FDA) has lifted a partial clinical hold on the Phase 1/2 VELA trial of […]